Atenolol
Atenolol is a beta-blocker taken by mouth. The US label read, for Tenormin, lists three uses: hypertension, to lower blood pressure; the long-term management of patients with angina pectoris; and, in hemodynamically stable patients with definite or suspected acute myocardial infarction, reducing cardiovascular mortality.
Also called Tenormin
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 1202; UNII 50VV3VW0TI. MeSH descriptor D001262 is Atenolol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Upsher-Smith Laboratories, LLC label for TENORMIN (atenolol), application NDA018240, effective 2025-09-18 in openFDA. Other atenolol labels in openFDA, from generic sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 5 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 5
- Phase 3 or 4
- 4
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 2 | 0 | 0 | 1 | 1 |
| Phase 3 | 0 | 1 | 0 | 1 |
| Phase 4 | 1 | 1 | 1 | 3 |
| All phases | 1 | 2 | 2 | 5 |
Conditions these trials study
- Hypertension (high blood pressure)
- Angina pectoris
- Cerebral small vessel disease
- Ischemic stroke
- Stroke
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Claims and evidence
Context People for whom the US label of atenolol (Tenormin) lists an indication: hypertension, angina pectoris, definite or suspected acute myocardial infarction
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Patients with hypertension
- Patients with angina pectoris needing long-term management
- Hemodynamically stable patients with definite or suspected acute myocardial infarction
- Excluded
- None stated
The US label of TENORMIN (atenolol), in the Upsher-Smith Laboratories, LLC version dated 2025-09-18 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure; for the long-term management of patients with angina pectoris; and for hemodynamically stable patients with definite or suspected acute myocardial infarction, to reduce cardiovascular mortality.
Applies to Recipient not specified People for whom the US label of atenolol (Tenormin) lists an indication: hypertension, angina pectoris, definite or suspected acute myocardial infarction
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-08
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-09-18
- Source state
- Current
- Version fingerprint
16fc3b394ebc3edfdc3713d69728e637bce0d7771e3e123eb168492146835def- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250918.
- Retrieved
- Source effective date
- 2025-09-18
- Source state
- Current
- Version fingerprint
16fc3b394ebc3edfdc3713d69728e637bce0d7771e3e123eb168492146835def- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
TENORETIC 100
No label from the application holder was found in the openFDA label dataset for application NDA018760. This page does not show another labeler's label in its place.
TENORMIN
No label from the application holder was found in the openFDA label dataset for application NDA018240. This page does not show another labeler's label in its place.
TENORMIN
No label from the application holder was found in the openFDA label dataset for application NDA019058. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified People for whom the US label of atenolol (Tenormin) lists an indication: hypertension, angina pectoris, definite or suspected acute myocardial infarction
The US label of TENORMIN (atenolol), in the Upsher-Smith Laboratories, LLC version dated 2025-09-18 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure; for the long-term management of patients with angina pectoris; and for hemodynamically stable patients with definite or suspected acute myocardial infarction, to reduce cardiovascular mortality.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reducing cardiovascular mortality in stable patients with definite or suspected acute myocardial infarction as an indication: Heart attack (myocardial infarction)
Applies to Recipient not specified People for whom the US label of atenolol (Tenormin) lists an indication: hypertension, angina pectoris, definite or suspected acute myocardial infarction
The US label of TENORMIN (atenolol), in the Upsher-Smith Laboratories, LLC version dated 2025-09-18 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure; for the long-term management of patients with angina pectoris; and for hemodynamically stable patients with definite or suspected acute myocardial infarction, to reduce cardiovascular mortality.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 3
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 5
Record details
- Record id
cardio:atenolol- Content hash
cc4c887dd5c1e57df4e6422f937acbb52a3bf8d2b1ef70454003e4cfd158085e